On the evening of February 7, Wan Bond (002082SZ) announced that Mr. Zhao Shouming, one of the actual controllers of the company, increased his holdings of the company's shares by 360 through centralized bidding in the secondary market on February 7, 2024560,000 shares, accounting for 05847%。
According to the announcement, Wanbond's implementation of the shareholding increase plan is based on the company's confidence in the future development and the recognition of long-term investment value, enhance investor confidence, safeguard the interests of small and medium-sized shareholders, and promote the company's sustainable, stable and healthy development.
According to public information, Wanbond Pharmaceutical Group, founded in 1970 and headquartered in Wenling, Zhejiang, is a high-tech enterprise specializing in the research and development, production and sales of modern Chinese medicine, chemical raw materials and preparations. Over the years, the company has always adhered to the road of integration of production, education and research, with a mature technology transformation platform, focusing on the layout of cardiovascular and cerebrovascular, nervous system and other disease fields, has formed a product pattern of "featuring natural plant medicine, mainly cardiovascular and cerebrovascular and nervous system drugs, supplemented by drugs in the respiratory system and other fields", and has two major intellectual property rights products - ginkgo biloba dripping pill and huperzine A injection.
In terms of product R&D and innovation, after years of efforts and accumulation, the company has established a technology development platform with strong competitive advantages, and has accumulated rich R&D experience in natural plant medicine separation and purification technology, drug release technology, chemical API synthesis technology, cardiovascular and cerebrovascular and nervous system drug process optimization and technological innovation. As of the first half of 2023, the company has 38 patents in the pharmaceutical manufacturing sector, including 32 invention patents and 6 utility model patents; One of the company's main products, Huperzine A, has obtained 1 US patent, 1 European patent and 1 Japanese patent.
Focusing on the field of medical devices, Wanbond has mastered a number of core technologies in the medical device industry, and has a number of professional technical research and development backbones in polymer materials, medicine, molds, mechanical automation, etc., and the technical research and development team has a high professional and technical level and rich industry experience.
It is worth mentioning that previously, the disposable sterile syringes of Kangkang Medical, a subsidiary of the company, were purchased with the first medical consumables in the Sanming Procurement Alliance in Group A, and obtained more than 50% of the agreed purchase volume in the alliance area, with a procurement cycle of 2 years. With the continuous promotion of the medical consumables procurement policy, the company's production capacity has been further released.
The return to this shareholding increase plan not only reflects the company's confidence in future development, but also conveys the determination of the company's management to share risks and benefits with shareholders. In the current complex and volatile global economic situation, the company is expected to stand out in the future market competition and achieve sustained and steady growth by virtue of its own advantages.